US discussion on value-based contracts is well underway, says report
A white paper with input from a host of experts from big pharma has looked into the extent to which the US market is moving towards value-based contracts that reward manufacturers on outcomes rather than volume.
The report, from event provider eyeforpharma has been published ahead of the Data, Evidence and Access Summit 2017 taking place in Philadelphia in November, and is titled Is the US market ready for value-based contracting?
Fee-for service arrangements in the USA mean that payment is made upon service and is therefore tied to volume. This system does not currently track quality, though the paper notes that moves towards linking the price of treatments, including pharmaceutical interventions, to the outcomes that they produce, are underway.
Private and public sectors exploring change
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze